title: Pembrolizumab associated hemophagocytic lymphohistiocytosis.
authors.affiliation: Hematology and Bone and Marrow Transplantation, University of Kentucky, Lexington, USA.
authors.forename: D
authors.initials: D
authors.lastname: Shah
authors.affiliation: Hematology and Bone and Marrow Transplantation, University of Kentucky, Lexington, USA.
authors.forename: R
authors.initials: R
authors.lastname: Shrestha
authors.affiliation: Hematology and Bone and Marrow Transplantation, University of Kentucky, Lexington, USA.
authors.forename: R
authors.initials: R
authors.lastname: Ramlal
authors.affiliation: Hematology and Bone and Marrow Transplantation, University of Kentucky, Lexington, USA.
authors.forename: J
authors.initials: J
authors.lastname: Hatton
authors.affiliation: Hematology and Bone and Marrow Transplantation, University of Kentucky, Lexington, USA.
authors.forename: H
authors.initials: H
authors.lastname: Saeed
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000139:chemically induced* / Q000276:immunology; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C582435:pembrolizumab